期刊
TOXICOLOGICAL SCIENCES
卷 138, 期 2, 页码 249-255出版社
OXFORD UNIV PRESS
DOI: 10.1093/toxsci/kfu005
关键词
nanomaterials; immune system; immunotoxicity; mast cells; drug carrier agents
类别
资金
- National Institute of Environmental Health Sciences [NIEHS-N01-ES-55538, NIEHS-R01-ES-019311, NIEHS-U19-ES019525]
- National Institute of Health [NIH/NCI 1-U54-CA151652-01, NIH/NCI 2-P30-CA016086]
- UNC University Cancer Research Fund
- Lilly Research Awards Program (LRAP)
The potential for human exposure to the diverse and ever-changing world of nanoscale materials has raised concerns about their influence on health and disease. The novel physical and chemical properties of these materials, which are associated with their small size, complicate toxicological evaluations. Further, these properties may make engineered nanomaterials (ENMs) a prime target for interaction with the immune system following uptake by phagocytes. Undesired effects on antigen-presenting cells and other phagocytic cells are of concern due to the high likelihood of ENM uptake by these cells. In addition, ENM interactions with lymphocytes and other cell types can contribute to a varied spectrum of possible effects, including inflammation, hypersensitivity, and immunomodulation. Furthermore, the mast cell (a type of immune cell traditionally associated with allergy) appears to contribute to certain inflammatory and toxic effects associated with some ENMs. Although incidental exposure may be undesirable, nanomedicines engineered for various clinical applications provide opportunities to develop therapies that may or may not intentionally target the immune system. The interaction between ENMs and the immune system and the resulting pharmacokinetic and phenotypic responses are critical factors that dictate the balance between toxicity and clinical efficacy of nanotherapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据